Business Context and Reporting Period
Company: Contineum Therapeutics, Inc. (CTNM)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2025
Business Overview: Contineum is a clinical-stage biopharmaceutical company focused on developing small molecule therapies for neuroscience, inflammation, and immunology (NI&I) indications. The company has no approved products and generates no product revenue. Its strategy relies on two primary drug candidates: PIPE-791 (wholly-owned) and PIPE-307 (licensed to Johnson & Johnson).
Key Financial Metrics
| Metric (in thousands) | 2025 | 2024 |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expenses | $51,522 | $38,422 |
| General & Administrative Expenses | $16,537 | $12,472 |
| Total Operating Expenses | $68,059 | $50,894 |
| Net Loss | $(59,978) | $(42,258) |
| Interest Income | $8,246 | $8,905 |
| Cash, Cash Equivalents & Marketable Securities | $262,900 | $204,760 |
| Accumulated Deficit | $(177,380) | $(117,402) |
Liquidity: As of December 31, 2025, the company held $262.9 million in cash, cash equivalents, and marketable securities. Management believes these resources are sufficient to fund operations for at least 12 months following the filing date.
Material Changes vs. Prior Period
- Increased Operating Loss: Net loss increased by $17.7 million (42%) to $60.0 million in 2025, driven primarily by a $13.1 million increase in R&D expenses and a $4.1 million increase in G&A expenses.
- R&D Expense Drivers: The increase in R&D was due to $9.0 million in higher CRO costs (primarily for the Phase 2 IPF trial of PIPE-791), $4.2 million in personnel costs, and $1.6 million in stock-based compensation. This was partially offset by a $3.3 million decrease in costs for the PIPE-307 VISTA trial.
- Capital Raises: In 2025, the company raised $93.0 million in net proceeds from a follow-on public offering and $19.0 million from an at-the-market (ATM) offering. In 2024, the company completed its IPO, raising $107.9 million in net proceeds.
- Cash Flow: Net cash used in operating activities increased to $55.3 million in 2025 from $32.8 million in 2024. Net cash provided by financing activities was $112.7 million in 2025.
Guidance, Outlook, and Risks
Clinical Pipeline Updates
- PIPE-791 (Lead Asset): A novel LPA1R antagonist for Idiopathic Pulmonary Fibrosis (IPF) and chronic pain.
- IPF: Initiated the Phase 2 PROPEL-IPF trial in December 2025. Enrollment of ~324 subjects is ongoing; completion projected for June 2028.
- Chronic Pain: Completed enrollment for a Phase 1b trial in Q4 2025. Top-line data expected in Q2 2026.
- Progressive MS: Development deferred pending additional funding.
- PIPE-307 (J&J Partnership): A selective M1R inhibitor for depression and Relapsing-Remitting Multiple Sclerosis (RRMS).
- RRMS: In November 2025, the Phase 2 VISTA trial reported top-line data showing acceptable safety but failed to meet primary and secondary efficacy endpoints. J&J has sole discretion on further development.
- Depression: J&J began recruiting for the Phase 2 Moonlight-1 trial in December 2024.
- CTX-343: Development deferred pending funding.
Management Commentary & Risks
- Financial Outlook: The company expects operating expenses to increase significantly as it advances clinical trials. It anticipates continuing to incur net losses for the foreseeable future.
- Capital Needs: Significant additional capital will be required to complete development and commercialization. Future funding may come from equity offerings, debt, or collaborations.
- Key Risks:
- Clinical Failure: Heavy dependence on PIPE-791 and PIPE-307. The failure of PIPE-307 in the RRMS trial highlights the risk of clinical development.
- Regulatory Uncertainty: FDA approval processes are unpredictable; no products are currently approved.
- Third-Party Dependence: Reliance on J&J for PIPE-307 commercialization and on Contract Manufacturing Organizations (CMOs) for supply chain.
- Government Policy: Potential impacts from healthcare reform, drug pricing negotiations (IRA), and FDA staffing changes.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $262.9 million cash balance against the projected burn rate, given the deferral of CTX-343 and PrMS programs.
- PIPE-307 Future: Monitor J&J's decision on whether to continue developing PIPE-307 for Depression (MDD) following the RRMS trial failure.
- PIPE-791 Phase 2 Data: Track the timeline and results of the PROPEL-IPF trial (completion projected 2028) and the chronic pain Phase 1b data (expected Q2 2026).
- Dilution Risk: Assess the impact of the remaining $55.4 million ATM capacity and potential future equity raises on shareholder dilution.
- Manufacturing Supply Chain: Confirm the stability of the API supply chain for PIPE-791, which is manufactured in China, amidst geopolitical tensions and the BIOSECURE Act.